Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver...

Area of Science:

• Medicinal Chemistry
• Enzymology
• Pharmacology

Background:

• Cytochrome P450 CYP26 enzymes regulate all-trans-retinoic acid (atRA) levels.
• Inhibiting CYP26 is a therapeutic strategy to boost endogenous atRA.
• Lack of selective inhibitors for CYP26A1 and CYP26B1 limits therapeutic development.

Purpose of the Study:

• To synthesize and characterize novel selective inhibitors of CYP26A1.
• To evaluate the potency and selectivity of these inhibitors.
• To assess the compounds' effect on atRA metabolism and activity in cellular models.

Main Methods:

• Chemical synthesis of nonazole compounds targeting CYP26A1.
• Enzyme inhibition assays to determine IC50 values and selectivity.
• Cell-based assays using HepG2 cells to measure atRA metabolism and RAR activation.

Main Results:

• Identification of a series of potent, nonazole CYP26A1 selective inhibitors with low nM potency.
• The lead compound, 3-{4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3-dioxolan-2-yl] phenyl}4-propanoic acid (24), demonstrated 43-fold selectivity for CYP26A1.
• Compound 24 and analogues inhibited atRA metabolism in HepG2 cells, enhancing atRA's potency for RAR activation.

Conclusions:

• The first potent and selective CYP26A1 inhibitors were successfully synthesized.
• These compounds effectively modulate atRA metabolism and signaling in vitro.
• The identified inhibitors hold promise for novel therapeutic strategies, including combination therapy with atRA.